Market Overview
Size, untreated pool, and prevalence
- Brevintel analysis values the market at USD 2.3 billion in 2025 ($2.3B), rising from USD 2.5 billion in 2026 to USD 4.6 billion by 2035 ($4.6B) at a 7.2% CAGR over 2026–2035 and 2026-2035.
- That path equals expansion from USD 2,300 million in 2025 to USD 4,600 million in 2035 rather than a one-time acute-care cycle.
- Zoetis led with over 19.5% market share in 2025; the top 5 players—Zoetis, Elanco Animal Health Incorporated, Merck Animal Health, Boehringer Ingelheim International, and Virbac—held 58%.
- About 20 million dogs worldwide remained untreated or undertreated for allergic skin conditions, so conversion and persistence matter more than prevalence alone.
- Banfield records showed environmental allergy cases in dogs rose 30.7% over a decade, while flea allergy cases in cats increased 67.3% as of July 2018.
- Published literature in 2023 places canine atopic dermatitis prevalence at 3–15% in broader populations, with higher incidence in dermatology referral caseloads.
- Banfield's analysis of more than 3 million dogs and cats found flea allergy prevalence of 1.8% in dogs and 2.0% in cats, while environmental allergy affected 3.6% of dogs and 0.4% of cats.
- The category covers antihistamines, corticosteroids, immunotherapy, oral medicines, injectables, and topical formulations for pruritus, flea allergy dermatitis, environmental allergy, food-related hypersensitivity, and atopic dermatitis.
Approved options and pathway design
- Apoquel Chewable was approved by the FDA in June 2023 (June 13, 2023) for allergic dermatitis and atopic dermatitis in dogs at least 12 months old.
- Zenrelia received FDA approval in September 2024 (September 19, 2024) for the same broad canine indication in dogs at least 12 months old.
- Cytopoint, an anti-IL-31 monoclonal antibody, previously received a USDA license in the United States and a positive EMA opinion in Europe.
- Competing oral JAK inhibitors and injectable biologics expand clinical choice, while immunotherapy's 7.8% CAGR, above the market-wide 7.2% rate, signals rising value on individualized management.
- Brevintel analysis finds manufacturers must support diagnostic confidence, owner adherence, and veterinary workflow because efficacy alone does not close the gap between symptomatic pets and sustained treatment.
Market Dynamics
Ownership, OTC access, and dermatology innovation
- Allergic skin disease is a long-duration veterinary condition requiring repeat assessment; referral-center prevalence is materially higher than broad population estimates.
- OTC antihistamines, including diphenhydramine, cetirizine, and chlorpheniramine, are commonly used off-label and support the antihistamines segment's 34.5% market share.
- APPA reported 95 million U.S. households owned a pet in its 2025 survey.
- AVMA reported 87.3 million dogs and 76.3 million cats in the United States, with average annual veterinary spending of USD 598 among dog-owning households and USD 529 among cat-owning households.
- In Europe, FEDIAF reported 306 million pets and 140 million pet-owning households.
- Cytopoint targets IL-31, while Apoquel Chewable and Zenrelia expand oral JAK-inhibitor options; Nextmune's PAX test uses molecular and extract-based allergen information for patient-specific immunotherapy.
- These developments raise the value of dermatology visits and reward commercially integrated delivery rather than isolated product launches.
- Rising ownership expands the pool from which diagnosis and repeat prescribing can occur; conversion is strongest with regular veterinary contact and ability to sustain recurring treatment cost.
Safety, home care, and progression friction
- The FDA-approved Zenrelia label includes a boxed warning concerning vaccination timing, and Apoquel Chewable labeling identifies restrictions for specific patient populations and infection-related considerations.
- Veterinarians may favor topical options, intermittent treatment, injectable biologics, or immunotherapy when systemic benefit-risk is less acceptable.
- Virbac markets dermatology products including topical, shampoo, cyclosporine, and skin-barrier offerings that can complement prescription care or delay a first consultation.
- Brevintel analysis finds the principal friction in treatment progression, not in the existence of clinical demand.
- The 7.2% market CAGR is consistent with durable growth, but not with frictionless adoption.
- Immunotherapy's faster 7.8% CAGR suggests part of the market is moving toward individualized, longer-term approaches even though diagnostics and protocols are more demanding.
Segmentation Analysis
Drug class
- Antihistamines account for 34.5% of market revenue, equivalent to USD 804.5 million in 2025, and are projected to grow at a 7.2% CAGR.
- Their scale reflects accessibility, lower acquisition cost, and utility in mild symptoms or multi-modal regimens rather than full displacement by higher-intensity therapies.
- Corticosteroids account for 24.2% of the market and are projected to grow at a 6.7% CAGR, remaining useful in acute control and cost-sensitive settings.
- Immunotherapy represents 29.9% of market revenue, or approximately USD 687.7 million in 2025, and is projected to expand at a 7.8% CAGR.
- Nextmune positions Artuvetrin Therapy and the PAX serum test as an integrated diagnostic and immunotherapy platform for companion-animal allergy management.
- Other drug classes account for 11.4% of revenue and are projected to grow at a 6.4% CAGR, covering immunomodulators, supportive dermatology products, and emerging approaches.
Pet type
- Dogs account for 65% of market demand and are projected to grow at a 7.2% CAGR, supported by oral JAK inhibitors, an IL-31-targeting biologic, and individualized immunotherapy.
- Cats represent 22.3% of revenue and are projected to grow at a 7.9% CAGR, the fastest pet-type rate, reflecting an underserved feline base.
- Rabbits hold an 8.2% share and are projected to grow at a 7.5% CAGR, remaining more dependent on adapted protocols than dedicated portfolios.
- Other pet types account for 4.1% of the market and are expected to grow at a 6.4% CAGR through specialist veterinary channels.
Route of administration
- Oral products account for 66.7% of market revenue and are projected to reach USD 3 billion by 2035 via tablets, chewables, capsules, and oral solutions.
- Apoquel Chewable was developed to address administration challenges; Zoetis reported 91.6% voluntary acceptance within five minutes in a 120-dog field study.
- Parenteral treatments hold a 20.3% share and are projected to grow at a 7.2% CAGR, with Cytopoint illustrating compliance advantages when daily oral dosing is impractical.
- Topical products represent 13.2% of revenue and are projected to grow at a 7.6% CAGR through localized sprays, shampoos, and skin-support formulations.
Distribution channel
- Veterinary hospital pharmacies account for 52.6% of the market and are projected to grow at a 7.3% CAGR because diagnosis, prescribing, injectable administration, and counseling often occur in the same practice.
- AVMA reported that 74.2% of U.S. dog owners visited a veterinary practice in 2024, supporting the clinical touchpoint for prescription conversion.
- Retail pharmacies represent 34.1% of demand and are projected to expand at a 7.0% CAGR for OTC products and prescribed oral treatments.
- Online pharmacies hold a 13.3% share and are projected to grow at a 7.7% CAGR as chronic allergy management suits scheduled refills.
- Brevintel analysis finds dogs remain the principal revenue pool at a 65% share, while cats' 7.9% CAGR and the 66.7% oral share elevate formulation and refill design as commercial variables.
Regional Outlook
North America and Europe
- North America accounts for 41.8% of the global market and is projected to grow at a 6.8% CAGR, with an approximately USD 961 million market in 2025.
- The U.S. market increased from USD 779.1 million in 2022 to USD 810.7 million in 2023, USD 845.6 million in 2024, and USD 884.5 million in 2025.
- FDA approvals for Apoquel Chewable and Zenrelia reinforce the U.S. role as an early commercialization market for canine allergy innovation.
- Canada is a developed companion-animal market tied to veterinary access, prescription dispensing rules, and urban specialist care.
- Europe accounts for 28.2% of global revenue and is projected to grow at a 7.1% CAGR, supported by 306 million pets and 140 million pet-owning households.
- The United Kingdom's pet population includes 10.6 million dogs, 10.8 million cats, and 800,000 rabbits, according to 2024 estimates.
- Germany, France, Italy, Spain, and the Netherlands add specialist dermatology, diagnostic-led immunotherapy, and extended seasonal demand.
Asia Pacific, Latin America, and Middle East & Africa
- Asia Pacific represents 20.7% of global revenue and is projected to grow at the fastest regional CAGR, 7.9%, from an approximately USD 476 million market in 2025.
- Zoetis reported Chinese approval of Apoquel Chewable in its 2024 earnings materials, while Japan is a comparatively mature high-engagement market.
- India's estimated 31 million pet dogs and 2.44 million pet cats indicate a large early-stage patient base still concentrated beyond major cities.
- Australia and South Korea add developed veterinary sectors and urban pet-humanization demand for recurring allergy management.
- Latin America accounts for 5.9% of global market revenue and is projected to grow at a 7.6% CAGR, led by expanding urban pet ownership and private veterinary care.
- Brazil is the region's largest opportunity, supported by an estimated 160 million pets, including around 60 million dogs and 30 million cats; Mexico and Argentina add urban and affordability-sensitive demand.
- Middle East & Africa represents 3.5% of global revenue and is projected to grow at a 6.5% CAGR, concentrated in South Africa and higher-income Gulf markets including Saudi Arabia and the UAE.
- Brevintel analysis treats regional growth as a difference in treatment penetration: North America's 41.8% share and USD 961 million 2025 market versus Asia Pacific's 7.9% CAGR from USD 476 million.
Competitive Landscape
Structure and recent approvals
- Zoetis led with over 19.5% share in 2025; the top 5 players held 58%.
- Zoetis reported USD 417 million in U.S. key dermatology revenue in 2024, with 17% operational growth.
- Zoetis combines Apoquel, Apoquel Chewable, and Cytopoint across oral and injectable settings.
- Elanco competes through Atopica and Zenrelia, whose September 19, 2024 FDA approval introduced another oral JAK-inhibitor option for dogs at least 12 months old.
- Boehringer Ingelheim International acquired Saiba Animal Health AG on September 3, 2024, adding a virus-like-particle therapeutic-vaccine platform.
- The FDA approved Apoquel Chewable on June 13, 2023 for dogs at least 12 months old, broadening administration options.
- Nextmune occupies a specialized position through PAX diagnostics and Artuvetrin Therapy; Antech Diagnostics, IDEXX Laboratories, and Neogen Corporation support the testing ecosystem.
- PetIQ's retail-oriented model is relevant where owners initially manage mild symptoms outside specialist settings.
Integrated producers
- Zoetis
- Elanco Animal Health Incorporated
- Merck Animal Health
- Boehringer Ingelheim International
- Virbac
Specialty suppliers
- Nextmune
- Ceva Santé Animale
- Dechra
- Vetoquinol
- Provetica
- Antech Diagnostics
- IDEXX Laboratories
- Neogen Corporation
- PetIQ